Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-NK Therapy for High-risk Lymphoma with Primary Sjogren's Syndrome
NCT06967038Phase 2Recruiting
- Start
- Feb 2025
- Primary completion
- Oct 2027
- Modality
- Gene Editing, Gene Silencing, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD19 CAR NK cells in lymphoma. Started Feb 2025; status: recruiting.
02
Drugs
CD19 CAR NK cells
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT06967038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06967038.